|
|
|
|
|
30.03.26 - 22:03
|
Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results (GlobeNewswire EN)
|
|
|
BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today announced the U.S. Food and Drug Administration (FDA) cleared the Investigational New Drug (IND) applications for the Company to proceed to a Phase 1b clinical trial with AKY-25191. AKY-2519 is a miniprotein radioconjugate targeting B7-H3, which is expressed in several solid tumor types including prostate and lung cancers, and is the second clinical stage miniprotein radioconjugate discovered using Aktis' proprietary platform. The Company's lead miniprotein radioconjugate, AKY-1189, targeting Nectin-4, is currently enrolling patients in a Phase 1b clinical study. Aktis' miniprotein radioconjugates are designed to selectively deliver actinium-225 (225Ac), a highly potent alpha-emitting radioisotope, ...
|
|
|
19.03.26 - 13:36
|
Convergent Therapeutics Appoints Radiopharmaceutical Industry Veteran Michael Rossi to its Board of Directors (Business Wire)
|
|
|
Rossi Brings Decades of Leadership as Convergent Advances its Alpha-based Radioantibody for Prostate Cancer to Late-Stage Clinical DevelopmentCAMBRIDGE, Mass.--(BUSINESS WIRE)--Convergent Therapeutics Inc., a clinical-stage biotechnology company developing next-generation alpha-emitting radioantibodies for the treatment of prostate cancer, today announced the appointment of Michael Rossi to its Board of Directors. Mr. Rossi brings more than 30 years of experience in radiopharmaceuticals, drug development, and commercial leadership to Convergent, as the Company completes its Phase 2 study of CONV01-α, a prostate specific membrane antigen (PSMA)-targeted Actinium-225 (Ac-225) radioantibody in patients with metastatic castration-resistant prostate cancer (mCRPC).
Mr. Rossi currently serves as CEO of SHINE SPECT USA, LLC, a leader in diagnostic radiopharmaceuticals. He previously served as President, CEO, and a board member of Y-mAbs Therapeutics, where he was appointed CEO in 2023 and led until its acquisit...
|
|
|
17.03.26 - 14:09
|
TerraPower Isotopes announces cGMP manufacturing facility (PR Newswire)
|
|
|
This new facility will expand TPI's actinium-225 production twentyfold. BELLEVUE, Wash., March 17, 2026 /PRNewswire/ -- TerraPower Isotopes® (TPI®) announced today that the company is building its flagship current Good Manufacturing Practices (cGMP) actinium-225 (ac-225) manufacturing......
|
|
|
24.02.26 - 14:03
|
Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate (GlobeNewswire EN)
|
|
|
BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AKY-1189 for the treatment of adult patients with locally advanced or metastatic urothelial cancer (mUC) who have progressed on or after prior systemic therapies. Generated using Aktis' miniprotein radioconjugate platform, AKY-1189 is designed to deliver actinium-225 (225Ac), a highly potent alpha-emitting radioisotope, to Nectin-4 expressing tumors. Approximately 80 – 90% of urothelial cancer patients show positive expression of Nectin-4....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
